'Girls Who Invest' Empowers Young Women to Get Into Finance
With only 1.1% of women and minorities running the asset management industry's $71.4 trillion in assets, the field is lacking diversity. Girls Who Invest, a non-profit organization, is using empowerment to try to change that. Seema Hingorani, Founder of Girls Who Invest, joined us at the New York Stock Exchange to share why she feels it is important to encourage young women to pursue careers in asset management.
Girls Who Invest is working towards the goal of getting 30% of investable assets managed by women by 2030. Hingorani says the lack of diversity is a pipeline problem. She adds that young women don’t even know about the industry and how impactful and rewarding it can be. Hingorani said there has been a cloud over the industry since the 2008 financial crisis. To reach the next generation of women, Girls Who Invest designed a 10-week summer program for college students.
President Trump's immigration policies have put up a roadblock to Girls Who Invest's international growth, Hingorani says. Girls Who Invest accepted fewer international students in 2017 than last year because several women struggled to obtain work visas. She says the policies hurt the talent pool because talented women aren’t getting interviews due to the fact they don’t have visas.
Jay Hatfield, chief investment officer for ICAP, joined Cheddar News to discuss how markets are reacting to labor market news and what the Federal Reserve will do next in terms of interest rates.
Kristin Cavallari, who first gained fame as a cast member of the MTV reality show Laguna Beach, is now the founder of a beauty company called Uncommon James. Cheddar News anchor Hena Doba took a walk with Cavallari to discuss her many business ventures.
Heardle, the name-that-tune game inspired by the Wordle craze, is being dropped by Spotify less than a year after the music-streaming giant acquired it.
Moderna and Merck & Co. have developed a cancer vaccine that cuts the risk of death or recurrence of most deadly skin cancer by 44 percent compared to Keytruda on its own, according to researchers.
